<DOC>
	<DOCNO>NCT02966821</DOCNO>
	<brief_summary>A phase II , single-arm , open-label , multicenter study assess efficacy safety sulfatinib second-line treatment patient surgically unresectable metastatic biliary tract carcinoma</brief_summary>
	<brief_title>Study Sulfatinib Second-line Treatment Patients With Biliary Tract Carcinoma</brief_title>
	<detailed_description>This study adopt Simon 's two-stage design method base primary endpoint 16-week PFS rate . In first stage , 16 patient accrue . If 3 few patient without progression death 16 patient week 16 , study stop . Otherwise , 16 additional patient accrue total 32 evaluable patient . Sulfatinib orally administer within 1 hour breakfast day ( QD ) every 28-day treatment cycle disease progression , death , intolerable toxicity protocol specify end-of-treatment criterion meet ( come first ) .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<criteria>1 . Provision write Informed Consent Form ( ICF ) prior study specific procedure 2 . Aged least 18 year 3 . Histologically cytologically confirm advanced BTC surgically unresectable metastatic , include extrahepatic cholangiocarcinoma ( EHCC ) , intrahepatic cholangiocarcinoma ( IHCC ) gallbladder biliary carcinoma ( GBC ) 4 . One prior treatment cytotoxic chemotherapy , treatment failure intolerable toxicity 5 . ECOG 01 6 . Patients must measurable lesion 1 . Antitumor therapy receive within 4 week prior initiation study treatment 2 . Previous therapy approve investigational antiVEGF ( VEGFR ) tyrosine kinase inhibitor monoclonal antibody 3 . Liver metastases ≥50 % liver volume 4 . ChildPugh classification score liver function＞ 7 5 . History presence serious hemorrhage ( &gt; 30 ml within 3 month ) , hemoptysis ( &gt; 5 ml blood within 4 week ) thromboembolic event ( include transient ischemic attack and/or stroke event ) within 12 month 6 . Active malignancy ( except definitively treat basal squamous cell carcinoma skin , carcinoma insitu cervix ) within past 5 year 7 . Patients receive CYP3A4 potent inducer inhibitor within 2 week 8 . Pregnancy ( positive pregnancy test first dose study treatment ) lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Sulfatinib</keyword>
	<keyword>Biliary Tract Cancer</keyword>
	<keyword>Second-line</keyword>
</DOC>